Browsed by
Tag: Adamis

ADAMIS PHARMACEUTICL (ADMP) – Looking Into Adamis Pharmaceuticals’s Return On Capital Employed

ADAMIS PHARMACEUTICL (ADMP) – Looking Into Adamis Pharmaceuticals’s Return On Capital Employed

In Q2, Adamis Pharmaceuticals (NASDAQ: ADMP) posted sales of $3.93 million. Earnings were up 9.63%, but Adamis Pharmaceuticals still reported an overall loss of $11.25 million. Adamis Pharmaceuticals collected $4.66 million in revenue during Q1, but reported earnings showed a $10.26 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Adamis Pharmaceuticals posted an ROCE of -0.49%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Adamis Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

For Adamis Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q2 Earnings Insight

Adamis Pharmaceuticals reported Q2 earnings per share at $-0.15/share, which did not meet analyst predictions of $-0.08/share.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source Article Read the rest

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

PR Newswire

NEW YORK, Oct. 12, 2020

NEW YORK, Oct. 12, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for DOYU, ADMP, ALT, FCEL, and OVID.



To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.


View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-douyu-adamis-pharmaceuticals-altimmune-fuelcell-energy-or-ovid-therapeutics-301150213.html

SOURCE InvestorsObserver

Source Article Read the rest